FDA
-
-
-
-
-
-
-
Vir Biotechnology reports 66% achieved undetectable hepatitis delta virus
-
-
-
-
-
-
-
Vir Biotechnology enrolls first patient in ECLIPSE 2 hepatitis delta trial
-
-
-
-
-
-
-
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
-
-
-
-
-
-
-
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
-
-
-
-
-
-
-
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
-
-
-
-
-
-
-
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
-
-
-
-
-
-
-
FDA Revises EMA For Vir (VIR) and GlaxoSmithKline's Sotrovimab Due to Omicron BA.2 Subvariant
-
328,148 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

